Cargando…

Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S

Detalles Bibliográficos
Autores principales:	Huynh, Angela, Arnold, Donald M., Michael, James V., Clare, Rumi, Smith, James W., Daka, Mercy, Ianosi-Irimie, Monica, McKenzie, Steven E., Kelton, John G., Nazy, Ishac
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860431/ https://www.ncbi.nlm.nih.gov/pubmed/35377937 http://dx.doi.org/10.1182/bloodadvances.2022007336

Ejemplares similares

Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Gabarin, Nadia, et al.
Publicado: (2022)

The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
por: Bissola, Anna-Lise, et al.
Publicado: (2022)

Longitudinal Characteristics of Anti-Platelet Factor 4 Immunoglobulin G in Vaccine-Induced Immune Thrombotic Thrombocytopenia
por: Huynh, Angela, et al.
Publicado: (2022)

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
por: Kanack, Adam J., et al.
Publicado: (2022)

Lessons from vaccine-induced immune thrombotic thrombocytopenia
por: Kelton, John Greenhow, et al.
Publicado: (2021)

Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects
por: Huynh, Angela, et al.
Publicado: (2021)

Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia
por: Li, Na, et al.
Publicado: (2021)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis
por: Kennedy, Vanessa E., et al.
Publicado: (2021)

SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia
por: Appelbaum, Jacob, et al.
Publicado: (2022)

Antibody Responses to Third-Dose mRNA Vaccines in Nursing Home and Assisted Living Residents
por: Zhang, Ali, et al.
Publicado: (2022)

Decline in Pathogenic Antibodies over Time in VITT
por: Schönborn, Linda, et al.
Publicado: (2021)

Epidemiology of VITT
por: Pai, Menaka
Publicado: (2022)

Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2022)

Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Gabarin, Nadia, et al.
Publicado: (2021)

Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
por: Dix, Caroline, et al.
Publicado: (2022)

Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US
por: Rodriguez, Elsa V. C., et al.
Publicado: (2021)

Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents
por: Breznik, Jessica A., et al.
Publicado: (2021)

Longitudinal Aspects of VITT
por: Schönborn, Linda, et al.
Publicado: (2022)

Timeline of heparin‐induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay
por: Warkentin, Theodore E., et al.
Publicado: (2019)

Monoclonal and Oligoclonal Anti-PF4 Antibodies Mediate VITT
por: Singh, Bandana, et al.
Publicado: (2021)

Huynh A, Arnold DM, Michael JV, et al. Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. Blood Adv. 2023;7(2):246-250.
Publicado: (2023)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Understanding VITT(ual) reality
por: Rauova, Lubica, et al.
Publicado: (2021)

The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19
por: Jevtic, Stefan D., et al.
Publicado: (2022)

Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin
por: Singh, B, et al.
Publicado: (2021)

Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
por: Kanack, Adam J., et al.
Publicado: (2022)

Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder
por: Venier, Laura M., et al.
Publicado: (2022)

A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination
por: Handtke, Stefan, et al.
Publicado: (2021)

COVID-19 vaccin et VITT
por: Pernod, G.
Publicado: (2021)

COVID-19 and VITT: same or different?
por: Arepally, Gowthami M.
Publicado: (2021)

ViTT: Vision Transformer Tracker
por: Zhu, Xiaoning, et al.
Publicado: (2021)

Second-dose VITT: rare but real
por: Pavord, Sue, et al.
Publicado: (2022)

Long VITT: A case report
por: Roberge, Guillaume, et al.
Publicado: (2023)

Vaccine-induced immune thrombotic thrombocytopenia: Updates in pathobiology and diagnosis
por: Jevtic, Stefan D., et al.
Publicado: (2022)

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia
por: Bourguignon, Alex, et al.
Publicado: (2021)

Combination of two complementary automated rapid assays for diagnosis of heparin‐induced thrombocytopenia (HIT)
por: Warkentin, Theodore E., et al.
Publicado: (2020)

High‐dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin‐CPB in a patient with recent SRA‐negative HIT‐thrombosis with persisting platelet‐activating antibodies
por: Koster, Andreas, et al.
Publicado: (2020)

Vaccination-induced thrombocytopenia and thrombosis (VITT) and pre-VITT: Do not miss (or misdiagnose) the new member of the thrombotic thrombocytopenias family
por: Noyé, Mickaël, et al.
Publicado: (2022)

Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy
por: Greinacher, Andreas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e27ss34t4lhn2hf3ko9lk2nu4t